^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AB-1015

    i
    Other names: AB-1015
    Associations

    News

    Trials
    Company:
    ArsenalBio
    Drug class:
    Mesothelin-targeted CAR-T immunotherapy, ALPP-targeted CAR-T immunotherapy, ALPPL2-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    2ms
    AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients with Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, Arsenal Biosciences, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    cyclophosphamide • AB-1015
    6ms
    AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=60, Recruiting, Arsenal Biosciences, Inc. | Trial primary completion date: Mar 2024 --> Dec 2024
    Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    cyclophosphamide • AB-1015
    1year
    Preclinical development of AB-1015, an integrated circuit T cell therapy containing an ALPG/MSLN logic gate and FAS/PTPN2 shRNA-miR, for the treatment of ovarian cancer (SITC 2023)
    Conclusions AB-1015 is specific for ALPG/P+MSLN+, demonstrates superior potency compared with logic gated T cells alone, and is resistant to ovarian TME suppression in preclinical studies. Based on these promising preclinical data, AB-1015 is being studied in a phase I clinical trial (NCT05617755).
    Preclinical
    |
    MSLN (Mesothelin) • FASLG (Fas ligand) • ALPG (Alkaline Phosphatase) • PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2)
    |
    MSLN expression • ALPG expression
    |
    AB-1015
    over1year
    Preclinical Development of AB-1015, an Integrated Circuit T Cell Therapy Containing an ALPG/MSLN Logic Gate and FAS/PTPN2 shRNA-miR, for the Treatment of Ovarian Cancer (ASGCT 2023)
    As a result, AB-1015 is capable of completely clearing these otherwise difficult-to-treat tumors in this model.In summary, AB-1015 is specific for ALPG/P+MSLN+, demonstrates superior potency, expansion, and persistence compared with logic gated T cells alone, and is resistant to ovarian TME suppression in preclinical studies. Based on these promising preclinical data, AB-1015 is being studied in a phase I clinical trial (NCT05617755) to assess the safety, pharmacokinetics, immunogenicity, and efficacy for patients with platinum-resistant ovarian cancer.
    Preclinical
    |
    MSLN (Mesothelin) • FASLG (Fas ligand) • ALPG (Alkaline Phosphatase) • PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2)
    |
    MSLN expression • ALPG expression
    |
    AB-1015
    almost2years
    AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=60, Recruiting, Arsenal Biosciences, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSLN (Mesothelin) • MUC16 (Mucin 16, Cell Surface Associated) • ALPG (Alkaline Phosphatase)
    |
    BRCA2 mutation • BRCA1 mutation • ALPG expression
    |
    cyclophosphamide • AB-1015
    almost2years
    AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Arsenal Biosciences, LLC
    New P1 trial
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSLN (Mesothelin) • MUC16 (Mucin 16, Cell Surface Associated) • ALPG (Alkaline Phosphatase)
    |
    BRCA2 mutation • BRCA1 mutation • ALPG expression
    |
    cyclophosphamide • AB-1015